News
BERGENBIO ANNOUNCES POSITIVE interim CLINICAL AND TRANSlaTIONAL DATA from Phase II trial of BEMCENTINIB IN COMBINATION WITH KEYTRUDA® IN checkpoint inhibitor refractory NSCLC PATIENTS
6 of 7 checkpoint inhibitor refractory cAXL-positive patients report clinical benefit 12 evaluable patients for cAXL…
Read More
BERGENBIO ANNOUNCES CHANGE TO PRESENTATION TIME AT Next Gen Immuno-Oncology Congress
Bergen, Norway, 24 June 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…
Read MoreBerGenBio to Present at the Upcoming Virtual European Biotech Investor Day 2020
Bergen, Norway, June 23, 2020 – BerGenBio, a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors…
Read MoreBERGENBIO TO PRESENT TOP LINE TRANSLATIONAL PHASE II DATA WITH BEMCENTINIB IN COMBINATION WITH KEYTRUDA® IN NSCLC PATIENTS AT Next Gen Immuno-Oncology Congress
Bergen, Norway, 15 June 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…
Read MoreBERGENBIO CONFIRMS FIRST COVID19 PATIENT DOSED WITH BEMCENTINIB IN ACCORD TRIAL
Bergen, Norway – 02 June 2020: BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel,…
Read MoreBERGENBIO ASA: RESULTS FOR THE FIRST QUARTER 2020
Bergen, Norway, 19 May 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…
Read More
Jonas Lies vei 91, 5009 Bergen, Norway
+ 47 559 61 159